JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02164500

Acronym

JeRiCHO

Enrollment

Registered

2014-06-16

Start date

2015-10-31

Completion date

2019-05-17

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Classical Hodgkin Lymphoma

Brief summary

The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Interventions

DRUGRuxolitinib

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* relapsed or refractory HL * ECOG \<= 2, * no major organ dysfunction * written informed consent

Exclusion criteria

* history of another primary malignancy ≤ 2 years * female patients who are pregnant or breast feeding * patients with a known history of HIV seropositivity * chronic active hepatitis

Design outcomes

Primary

Measure	Time frame
overall response rate	8 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026